Pasar al contenido principal

Refine your results

Filtros
Buscar
Include spaces in matter number if applicable. Ex.: 182 3125
Fecha
Displaying 12261 - 12280 of 18382
Early Termination Notices

20020892: Warburg Pincus Private Equity VIII, L.P.; Agere Systems Inc.

… 20020892: Warburg Pincus Private Equity VIII, L.P.; Agere Systems Inc. HSR Early Termination Notice 20020892: Warburg Pincus Private Equity VIII, L.P.; Agere Systems Inc. 20020892 Agere Systems Inc. Agere Systems Inc. Warburg Pincus Private Equity VIII, L.P. … 20020892: Warburg Pincus Private …
Date
Acquiring Party
Warburg Pincus Private Equity VIII, L.P.
Acquired Party
Agere Systems Inc.
Acquired Entities
Agere Systems Inc.
Advocacy Filings

FTC Staff Comment Before Federal Energy Regulatory Commission Concerning Standardized Transmission Service and Wholesale Electric Market Design

… FTC Staff Comment Before Federal Energy Regulatory … Design Enviado por wfg-adm109 el Lun, 01/07/2002 - 00:00 FTC Staff Comment Before Federal Energy Regulatory … Electric Market Design v020018.pdf Advocacy Filing … FTC Staff Comment Before Federal Energy Regulatory …
Date
Matter Number
V020018
Advocacy Filings

FTC and Department of Justice Comment to the North Carolina State Bar Concerning Proposed State Bar Opinions Concerning Non-Attorney Involvement in Real Estate Transactions

… FTC and Department of Justice Comment to the North Carolina State Bar Concerning Proposed State Bar Opinions Concerning Non-Attorney … Enviado por wfg-adm109 el Lun, 01/07/2002 - 00:00 FTC and Department of Justice Comment to the North Carolina …
Date
Matter Number
V020006
Cases and Proceedings

Biovail Corporation

… for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further …

The Commission charged Biovail Corporation with illegally acquiring an exclusive patent license for Tiazac, a pharmaceutical used to treat high blood pressure and chronic chest pain. The complaint further alleged that Biovail, in an effort to maintain its monopoly, wrongfully listed the acquired license in the U.S. Food and Drug Administration’s “Orange Book” for the purpose of blocking generic competition to its branded Tiazac. The consent order requires Biovail to divest part of its exclusive rights to DOV; prohibits the firm from taking any action that would trigger additional statutory stays on final FDA approval of a generic form of Tiazac; and also prohibits Biovail from wrongfully listing any patents in the Orange Book for a product for which the company already has an New Drug Application from the FDA.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
011 0094
Docket Number
C-4060
HSR Informal Interpretations

0206004 Informal Interpretation

… 0206004 Informal Interpretation 0206004 Informal Interpretation From: (redacted) To: Michael Verne Date: 6/26/02 … it also get the benefit of filings made by its former UPE prior to the time that it was owned by the UPE? Here's the …
Date
Rule
802.21
No 802.21 does not apply. (1) The original acquisition by A of B voting securities contained no information on C. (2) More importantly, C never held and does not currently hold any voting securities...
HSR Informal Interpretations

0206003 Informal Interpretation

… 0206003 Informal Interpretation 0206003 Informal Interpretation From: (redacted) To: Michael Verne Date: 6/25/02 … on the current number of shares outstanding, the purchase price is exactly $99,937,310. If a sufficient number of …
Date
Rule
801.10
Advised that if there is no reasonable basis for estimating the number of options that will be exercised, the acquisition price is undetermined and the value is the fair market value. N. Ovuka concurs...
HSR Informal Interpretations

0206007 Informal Interpretation

… 0206007 Informal Interpretation 0206007 Informal Interpretation From:(Redacted) To:FTC.SERIUS ( Novuka@ftc.gov ) Date: 6/21/02 4:53PM Subject: HSR analysis Dear …
Date
Rule
802.4
6/23 Confirmed advice by phone. Position only applies to minority interest, and not if it results in 100% of the LP interests. If issuer holds a majority interest in an LP, the value of the underlying...
Cases and Proceedings

FMC Corporation and Asahi Chemical Industry Co., Ltd

A consent order settled charges that FMC and Asahi Chemical Industry Co. Ltd. of Japan entered into a conspiracy to divide the world market for microcrystalline cellulose (MCC), a binder used in making pharmaceutical tablets, into two territories. According to the complaint, FMC allegedly agreed not to sell the pharmaceutical to customers in Japan or East Asia without Asahi Chemical's consent, while Asahi Chemical agreed not to sell the pharmaceutical to customers in North America or Europe without the consent of FMC. The final order prohibits such behavior in the future and restricts FMC from acting as the U.S. distributor for any competing manufacturer of microcrystalline cellulose (including Asahi Chemical) for 10 years. In addition, for five years, FMC is prohibited from distributing in the United States any other product manufactured by Asahi Chemical.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
981 0237
Docket Number
C-4050
Amicus Briefs

Michael Erikson v. Ameritech Corporation

… memorandum for the Federal Trade Commission opposing approval of a class action settlement, which included a large award of attorney's fees while providing no substantial benefits to consumers Amicus Brief …
Date
Citation Number
99CH 18873
Amicus memorandum for the Federal Trade Commission opposing approval of a class action settlement, which included a large award of attorney's fees while providing no substantial benefits to consumers
Displaying 12261 - 12280 of 18382
Return to top